Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints and data collection requirements for clinical studies.
暂无分享,去创建一个
Randall J. Lee | A. Camm | H. Diener | A. Camm | R. Cappato | C. Blomström-Lundqvist | J. Brachman | J. Saver | D. Holmes | M. Näbauer | S. Schneider | R. Byrne | S. Kar | T. Lewalter | R. Ibrahim | H. Sievert | C. Ruiz | D. Lakkireddy | K. Tiemann | O. Soliman | A. Tzikas | S. Gafoor | R. Lee | J. Saver | Carlos E Ruiz | Randal J. Lee
[1] B. Meier,et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[2] P. Kolh,et al. 2014 ESC/EACTS guidelines on myocardial revascularization. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[3] Michael Glikson,et al. EHRA / EAPCI expert consensus statement on catheter-based left atrial appendage occlusion , 2014 .
[4] Saibal Kar,et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. , 2014, JAMA.
[5] Eugene Yang,et al. A clinician’s perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation – full speed ahead or proceed with caution? , 2014, Vascular health and risk management.
[6] M. Price,et al. Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium. , 2014, Journal of the American College of Cardiology.
[7] M. Price,et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. , 2014, Journal of the American College of Cardiology.
[8] D. Singer,et al. Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. , 2014, American heart journal.
[9] E. Tuzcu,et al. Percutaneous left atrial appendage occlusion for stroke prophylaxis in nonvalvular atrial fibrillation: a systematic review and analysis of observational studies. , 2014, JACC. Cardiovascular interventions.
[10] A. Maree,et al. Significance of the learning curve in left atrial appendage occlusion with two different devices , 2014, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[11] M. Mack,et al. Left atrial appendage occlusion: opportunities and challenges. , 2014, Journal of the American College of Cardiology.
[12] Akshay S. Desai,et al. Standardized Definitions for Cardiovascular and Stroke Endpoint Events in Clinical Trials , 2014 .
[13] W. Budts,et al. Transcatheter left atrial appendage closure for stroke prevention in atrial fi brillation with Amplatzer cardiac plug: the Belgian Registry , 2013, Acta cardiologica.
[14] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[15] C. Palmieri,et al. Tools and Techniques Clinical: transcatheter closure of left atrial appendage using the Amplatzer™ Cardiac Plug. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[16] K. Kuck,et al. New technical and anticoagulation aspects for left atrial appendage closure using the WATCHMAN® device in patients not taking warfarin. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[17] J. Saw,et al. Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy. , 2013, Journal of the American College of Cardiology.
[18] Frederick T. Han,et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. , 2013, Journal of the American College of Cardiology.
[19] Petr Neuzil,et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). , 2013, Journal of the American College of Cardiology.
[20] A. Camm,et al. An update and current expert opinions on percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[21] A. Massumi,et al. Initial experience with a novel percutaneous left atrial appendage exclusion device in patients with atrial fibrillation, increased stroke risk, and contraindications to anticoagulation. , 2013, The American journal of cardiology.
[22] P. Neužil,et al. Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) Trial , 2013, Circulation.
[23] M. Mack,et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. , 2012, The Journal of thoracic and cardiovascular surgery.
[24] Gerhard Hindricks,et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[25] Jeroen J. Bax,et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. , 2012, European heart journal.
[26] Fred S Apple,et al. Third universal definition of myocardial infarction , 2012 .
[27] M. Mack,et al. Exclusion of the left atrial appendage with a novel device: early results of a multicenter trial. , 2011, The Journal of thoracic and cardiovascular surgery.
[28] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[29] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[30] Marco Valgimigli,et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.
[31] Saibal Kar,et al. Safety of Percutaneous Left Atrial Appendage Closure: Results From the Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF (PROTECT AF) Clinical Trial and the Continued Access Registry , 2011, Circulation.
[32] P. Serruys,et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium , 2010, European heart journal.
[33] H. Alkadhi,et al. Left atrial appendage clip occlusion: early clinical results. , 2010, The Journal of thoracic and cardiovascular surgery.
[34] M. Rosenqvist,et al. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. , 2010, European heart journal.
[35] D Bergqvist,et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.
[36] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[37] Maurice Buchbinder,et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial , 2009, The Lancet.
[38] S. Yusuf,et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. , 2009, American heart journal.
[39] E. Blackstone,et al. Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography. , 2008, Journal of the American College of Cardiology.
[40] M. Aguilar,et al. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.
[41] John A Kellum,et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury , 2007, Critical care.
[42] E. Lonn,et al. Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. , 2005, American heart journal.
[43] I. Kronzon,et al. Surgical left atrial appendage ligation is frequently incomplete: a transesophageal echocardiograhic study. , 2000, Journal of the American College of Cardiology.
[44] J. Odell,et al. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. , 1996, The Annals of thoracic surgery.